查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553451

免疫調節劑市場規模、佔有率、趨勢分析報告：按解決方案、產品、應用、地區、細分市場預測，2024-2030

Immunomodulators Market Size, Share & Trends Analysis Report By Solution, By Product (Immunosuppressants, Immunostimulants), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

免疫調節劑市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球免疫調節劑市場規模將達到3.298億美元，2024年至2030年複合年成長率為6.2%。

預計該市場將主要受到知名公司採用的高研發投資的推動，從而導致新的治療先進藥物的大規模生產。因此，免疫調節劑市場預計將以前所未有的速度充斥藥物，為許多自體免疫疾病和發炎疾病提供高效的治療選擇。

此外，預計抗藥性的增加將增加開發具有標靶治療機制的新一代免疫調節劑的臨床緊迫性。上述因素的綜合影響預計將在預測期內提供顯著的成長機會。

此外，主要企業的快速成長預計不僅會提高患者而且還會提高醫生對免疫調節劑效用的認知。預計這將在預測期內進一步擴大免疫調節劑產業的成長潛力。

此外，單株抗體擴大應用於多種適應症，如多發性硬化症、克隆氏症、類風濕性關節炎和非何傑金氏淋巴瘤，預計將在預測期內推動免疫調節劑業的發展。單株抗體在自體免疫疾病中具有重要意義，一致的產品核可數量預計將成為擴大成長範圍的因素。

免疫調節劑市場報告亮點

  • 由於移植手術的增加以及防止器官排斥的需要，2023年免疫抑制劑在該產品類別中佔據最大佔有率。
  • 由於腎臟、肝臟、心臟和肺移植的使用和收益增加，到 2023 年，抗體將佔免疫抑制藥物的壓倒性佔有率。
  • 由於用於治療愛滋病毒、癌症和多發性硬化症的學名藥活化的流入減少，預計活化將出現高速成長。
  • 2023年，由於有大量參與大規模商業化的老牌製藥公司，北美主導了全球免疫調節劑市場。
  • 領先的參與企業正在實施研究和臨床合作策略，以創造新藥並獲得競爭優勢。
  • 例如，2024年3月，Ability Biologics完成種子輪資金籌措，總投資額達1,800萬美元。該資金將用於開發創新且高度針對性的免疫調節劑。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章全球免疫調節劑市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球免疫調節劑市場分析工具
    • 波特的分析
    • PESTEL分析

第4章全球免疫調節劑市場：按產品分類的估計和趨勢分析

  • 細分儀表板
  • 全球免疫調節劑市場：2023 年和 2030 年產品變化分析
  • 免疫抑制劑
  • 免疫促效劑

第5章全球免疫調節劑市場：按應用估計和趨勢分析

  • 細分儀表板
  • 全球免疫調節劑市場：2023 年和 2030 年應用變化分析
  • 腫瘤學
  • 呼吸系統
  • HIV
  • 其他

第6章 全球免疫調節劑市場：區域估計與趨勢分析

  • 2023 年和 2030 年全球免疫調節劑市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc.
    • Abbott
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Merck &Co., Inc.
    • Biogen
    • Pfizer Inc.
簡介目錄
Product Code: GVR-1-68038-318-8

Immunomodulators Market Growth & Trends:

The global immunomodulators market size is expected to reach USD 329.8 million by 2030, expanding at a CAGR of 6.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to be predominantly driven by high R&D investments employed by prominent companies, resulting in the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.

In addition, increasing drug resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.

Furthermore, the burgeoning presence of the key players is expected to promote the awareness levels pertaining to the benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.

In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn's disease, rheumatoid arthritis, and Non-Hodgkin's Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.

Immunomodulators Market Report Highlights:

  • Immunosuppressant held the largest share of the product segment in 2023, owing to the increasing number of transplantation procedures and need to prevent organ rejection
  • Antibodies held the dominant share of immunosuppressant in 2023, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
  • Immunostimulants expected to grow lucratively as a result of the lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
  • In 2023, North America dominated the global immunomodulators market owing to the presence of a wide number of established pharmaceutical companies involved in extensive commercialization
  • The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
  • For instance, In March 2024, Ability Biologics concluded its seed funding, securing a total of USD 18 million in investment. This capital is expected to be directed towards the development of innovative and highly targeted immunomodulators.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Immunomodulators Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Immunomodulators Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Immunomodulators Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Immunomodulators Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Immunosuppressants
    • 4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunostimulants
    • 4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Immunomodulators Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Immunomodulators Market: Applicaton Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Respiratory
    • 5.4.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. HIV
    • 5.5.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Immunomodulators Market: Regional Estimates & Trend Analysis

  • 6.1. Global Immunomodulators Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Immunomodulators Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. F. Hoffmann-La Roche Ltd
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Amgen Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Abbott
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Johnson & Johnson Services, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Novartis AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Eli Lilly and Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Bristol-Myers Squibb Company
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck & Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives
    • 7.4.9. Biogen
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/ Strategic Initiatives
    • 7.4.10. Pfizer Inc.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/ Strategic Initiatives